Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ANS Girds As David To Medtronic's Goliath In Neuromodulation Market

This article was originally published in The Gray Sheet

Executive Summary

Advanced Neurostimulation Systems will launch its line of internal pulse generators (IPGs) for the treatment of chronic pain in the U.S. later this year should FDA decide to downclassify the devices from Class III to Class II later this month, CEO Chris Chavez told investors at the First Union 2000 Brain and Spine Symposium in New York City Jan. 19.
Advertisement

Related Content

FDA Moving Forward On Implantable Spinal Stimulation Downclassification
FDA Moving Forward On Implantable Spinal Stimulation Downclassification
Downclassification Of Implantable Spinal Cord Stimulators Recommended
Downclassification Of Implantable Spinal Cord Stimulators Recommended
Advertisement
UsernamePublicRestriction

Register

MT012842

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel